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Abstract: Many tumors produce factors that affect cell-cycle and cell proliferation. In the present study we have analyzed 
the effect of a mammary-tumor extract injection on the mitotic activity of several organs in young male C3H/S mice 
previously standardized for circadian periodicity. One-half of the animals received an intraperitoneal EA21b tumor extract 
dose at 16:00 h, while the other half received saline. Animals were sacrificed on the following day at 08:00, 12:00 or 16:00 h, 
4 h after receiving an injection of colchicine by the same route. Samples of duodenum, kidney, liver, and submaxillary gland 
were excised and processed for hematoxylin-eosin staining. Mitotic indices, expressed as the number of colchicine-arrested 
metaphases per 1,000 nuclei, were assessed in convoluted tubule epithelium, duodenal crypt enterocytes, hepatocytes and 
submaxillary gland ductal and acinar sialocytes. All values were expressed as mean ± SEM. Statistical analyses were 
performed by ANOVA, Bonferroni and Student’s t-tests. In contrast to the mitotic indices reductions observed in renal 
convoluted tubules cells and duodenal crypt enterocytes, neither the submaxillary gland nor the liver were found to contain 
cell types whose mitotic activity was affected by the tumor extract. We conclude that EA21b mammary carcinoma contains 
one or more factors that inhibit the proliferation of selected populations of normal cells.
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Introduction
Neoplastic tissues have long been investigated as a 
potential source of cell-growth regulators (Malmgren 
1956; Malmgren & Mills 1961; Badran et al. 1985a; 
Moreno et al. 1992). Research has been aimed mainly 
at the characterization of tumor cells’ alterations that 
render them insensitive to mechanisms regulating cell 
proliferation (Mackay et al. 1995; Huitfeldt et al. 1996) 
and cell death (Fantin & Leder 2006). The pioneering 
work by Malmgren (1956) demonstrated the presence of 
a mitogen extracted from a mammary carcinoma with 
specific activity in adult mouse liver (Malmgren 1956; 
Malmgren & Mills 1961). A similar line of research car­
ried out in our laboratory in murine tumors allowed us 
to report that EA34 mammary carcinoma has a growth­
promoting activity that is specific for prepuberal mouse 
hepatocytes (Moreno et al. 1992; Flamini et al. 1996).
These observations led us to explore the action 
of EA21b mammary-carcinoma extracts on the prolif­
eration of various selected cell populations in young 
mice from liver, kidney, duodenum and submaxillary 
gland, employing the mitotic arrest technique. Results 
obtained from those experiments are reported and dis­
cussed in this communication.
Material and methods
Animals
Thirty nine male four-week old C3H/S inbred mice from 
the Embryology, Biology and Histology Institute (School 
of Medical Sciences, National LTniversity of La Plata) were 
used. Animals weighed 15.1 ± 0.26 g at the time of sacrifice. 
Mice were housed in individual cages under standard con­
ditions for circadian periodicity analysis in a temperature- 
controlled room at 22 ± 2 C with a 12-h alternating light­
dark cycle beginning at 06:00 h. Tap water and pellet food 
were provided ad. libitum. Housing, feeding and handling 
conditions secured animal welfare according to the specific 
international laws.
Tumor
Subline b from the EA21 transplantable murine mammary 
carcinoma was employed. The abbreviation refers to the fol­
lowing: E, espontáneo (spontaneous); A, originating in the 
C3H/Avy strain of mice; 21, the twenty-first tumor line aris­
ing from the Embryology, Biology and Histology Institute 
laboratory stock. The tumor strain was maintained by serial 
subcutaneous transplants into female adult C3H/S-strain 
mice. EA21 is a highly undifferentiated and invasive tumor; 
its major architectural pattern includes rounded tumoral 
masses, with several layers of dark-stained epithelial cells. 
Cancerous cells also present a small cytoplasm and a big 
hyperchromatic nucleus. A reduced lumen may be observed
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Fig. 1. Arrows point colchicine metaphases in duodenal crypt enterocytes (upper left image; 40x), hepatocytes (upper right image; 
lOOx), convoluted tubules epithelia (bottom left image; lOOx), and acinar sialocytes (bottom right image; lOOx). Bar scale: 10 pm. 
Hematoxiline-eosine.
in tumoral masses. The carcinoma kills 50% of the bearers 
within five weeks.
Tumor extract preparation
Tumors from three donors were pooled for extract prepara­
tion. Small pieces showing neither necrosis nor hemorrhage 
were teased away and placed for homogenization in a Potter- 
Dual tissue grinder at 0 C. The tissue was disrupted in dis­
tilled water (1:9, w/v) at a rate of 10 strokes within s 
and the resulting homogenate centrifuged at 4,000 rpm and 
4 C for 20 min. The supernatant was immediately injected.
Experimental design
Recipient animals were injected intraperitoneally with ei­
ther tumor extract (2 mg/0.01 mL /g body weight) or 0.01 
mL saline/g body weight at 16:00 h. The time of day for 
this procedure was selected according to previous work for 
it corresponds to the end of Gi phase for the majority of cells 
destined to enter mitosis at 12:00 h. Mice were sacrificed by 
decapitation and exanguination at 08:00/16, 12:00/20, and 
16:00/24 (time of day/h post injection) (n = 6-7). Each 
lot of animals received a 2 ;tg/g body weight colchicine in­
traperitoneal injection 4 h before sacrifice. Specific times for 
sacrifice were chosen due to the knowledge that mitotic ac­
tivity highest values for most cell populations under study 
occur at/around 12:00 h in these diurnally-synchronized 
mice (Barbeito et al. 2002b; Bjarnason & Jordan 2002).
Mitotic activity measurement
Liver, kidney, duodenum, and submaxillary gland samples 
were fixed in 10% (v/v) buffered formalin and processed 
for histology. The following cell-types were monitored: kid­
ney convoluted tubule cells, duodenal crypt enterocytes, 
hepatocytes and ductal and acinar sialocytes. The scoring 
of colchicine-arrested metaphases on 140 microscopic fields 
and the total number of cell nuclei within every tenth field 
was performed for liver, kidney and submaxillary gland tis­
sue samples at a l,500x magnification. The monitoring in 
duodenal samples comprised only longitudinally cut crypt 
sections divided into three regions: cell tiers 1-4, 5-12, and 
13-20, proceeding from crypt bottom to top, respectively. 
All slides were encoded and the scoring was performed by 
MAF and NVG blinded to experimental conditions. Mitotic 
indices were expressed as the number of colchicine-arrested 
metaphases per 1,000 nuclei.
Statistical analysis
The mean value ± SEM of the mitotic indices were calcu­
lated for each cell population monitored. Comparisons be­
tween mean values for each lot and time-points were per­
formed by ANOVA test. Bonferroni was used as post-test. 
Student’s t-test was employed to analyze mean values for 
each treatment.
Results
The colchicine effect was detected in all cell popula­
tions under study by the observation of cell-arrested 
metaphases in tissue sections (Fig. 1).
The results found in our survey on selected cell 
populations are presented in Tables 1-5 as follows: 
Tab. 1 - convoluted-tubule cells; Tab. 2 - duodenal
Unauthenticated
Download Date | 8/23/19 11:20 PM
240 M.A. Flamini et al.
Table 1. Mitotic activity of kidney convoluted-tubule cells.a
Time of day/ Saline EA2 lb extract
h post injection ------------------------  ----------------------------------
X ± SE n X ± SE n p
08:00/16 4.56 ± 0.83 7 3.78 ± 0.44 6 NS
12:00/20 4.68 ± 0.82 7 1.55 ± 0.16 7 NS
16:00/24 2.32 ± 0.43 6 1.10 ± 0.25 6 NS
08+12+16 3.85 ± 0.47 20 2.14 ± 0.31 19 <0.005
Table 3. Mitotic activity of hepatocytes.a
Time of day/
i post injection
Saline EA21b extract
.V ± SE n .V ± SE n P
08:00/16 0.53 ± 0.23 7 0.52 ± 0.20 6 NS
12:00/20 1.28 ± 0.33 7 0.62 ± 0.11 7 NS
16:00/24 0.41 ± 0.05 6 0.29 ± 0.10 6 NS
08+12+16 0.74 ± 0.11 20 0.48 ± 0.08 19 NS
a X: mean; SE: standard error; n: number of animals; pi statis­
tical signification; NS: not significant. 
a X: mean; SE: standard error; n: number of animals; pi statis­
tical signification; NS: not significant.
crypt enterocytes; Tab. 3 - hepatocytes; Tab. 4 - ductal 
syalocites; and Tab. 5 - acinar sialocytes.
A significant mitotic activity decrease in both renal 
convoluted tubules cells (Tab. 1) and duodenal-crypt 
enterocytes from tumor-extract injected mice (Tab. 2) 
over saline administered animals was found.
The renal convoluted cells exhibited a significant 
cell-proliferation diminution at 12:00/20 (p < 0.01) 
(Tab. 1). The mitotic index reduction observed in the 
duodenal crypts enterocytes at cell tiers 1-20 was re­
stricted to a mitotic index peak at 12:00/20 (p < 0.05) 
and to the average mitotic value of all time-points as­
sessed (p < 0.05) (Tab. 2). The crypt zonal study de­
tected that the decrease in mitotic activity was local­
ized in cell tiers 13-20. Moreover, both treatments ren­
dered similar mitotic activity variations; cell tiers 5-12 
showed the highest mitotic index whereas cell tiers 1-4 
exhibited the minimal mitotic values.
In contrast to the mitotic indices changes observed 
in renal convoluted tubules cells and duodenal crypt en­
terocytes, neither the submaxillary gland nor the liver
Table 4. Mitotic activity of ductal sialocytes.a
Time of day/ 
h post injection
Saline EA21b extract
X ± SE n X ± SE n P
08:00/16 6.67 ± 1.40 7 6.85 ± 1.76 6 NS
12:00/20 6.69 ± 0.51 7 5.62 ± 0.59 7 NS
16:00/24 3.15 ± 0.44 6 2.00 ± 0.36 6 NS
08+12+16 5.50 ± 0.63 20 4.82 ± 0.77 19 NS
a X: mean; SE: standard error; n: number of animals; pi statis­
tical signification; NS: not significant.
were found to contain cell types whose mitotic activity 
was affected by the tumor extract (Tabs 3-5).
Discussion
Our results showed that two out of the eight cell pop­
ulations under study exhibited a significant mitotic ac-
Table 2. Mitotic activity of duodenal crypt enterocytes.a
Tiers
Time of day/ 
h post injection
Saline Tumor extract
X ± SE n X ± SE n P
a 08:00/16 52.68 ± 12.78 7 41.67 ± 5.74 6 NS
12:00/20 64.29 ± 4.66 7 48.21 ± 6.20 7 NS
16:00/24 44.79 ± 15.42 6 61.46 ± 8.44 6 NS
08+12+16 54.38 ± 6.52 20 50.33 ± 4.17 19 NS
b 08:00/16 169.20 ± 25.18 7 127.61 ± 15.80 6 NS
12:00/20 192.41 ± 14.78 7 149.56 ± 11.99 7 NS
16:00/24 161.98 ± 15.38 6 194.80 ± 20.97 6 NS
08+12+16 175.16 ± 11.03 20 156.91 ± 10.93 19 NS
c 08:00/16 108.04 ± 16.06 7 58.34 ± 9.93 6 NS
12:00/20 134.38 ± 12.21 7 79.02 ± 15.79 7 NS
16:00/24 95.84 ± 8.93 6 91.67 ± 14.67 6 NS
08+12+16 113.60 ± 8.05 20 76.48 ± 8.25 19 <0.003
d 08:00/16 121.43 ± 17.90 7 82.71 ± 9.74 6 NS
12:00/20 143.57 ± 9.88 7 101.07 ± 10.65 7 <0.05
16:00/24 112.08 ± 9.18 6 126.88 ± 11.79 6 NS
08+12+16 126.37 ± 7.87 20 103.42 ± 7.19 19 <0.04
a X: mean; SE: standard error; n: number of animals; pi statistical signification; NS: not significant; a: tiers 1-4; b: tiers 5-12; c: tiers 
13-20; d: tiers 1-20.
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Table 5. Mitotic activity of acinar sialocytesT
Time of day/ 
h post injection
Saline EA21b extract
X ± SE n X ± SE n P
08:00/16 1.80 ± 0.32 7 2.81 ± 0.64 6 NS
12:00/20 1.42 ± 0.66 7 1.36 ± 0.29 7 NS
16:00/24 0.49 ± 0.09 6 0.55 ± 0.20 6 NS
08+12+16 1.24 ± 0.27 20 1.57 ± 0.32 19 NS
a X: mean; SE: standard error; n: number of animals; p: statis­
tical signification; NS: not significant-
tivity reduction. The results obtained for renal con­
voluted tubules cells and duodenal crypt enterocytes 
would be consistent with the following plausible expla­
nations: (a) EA21b mammary carcinoma extracts con­
tain factor/s that is at least potentially inhibitory to 
cell-cycle progression; (b) both renal convoluted tubules 
and duodenal-crypt epithelial cells respond to these pu­
tative growth inhibitors, thus suggesting that these cell 
populations constitute natural target cells and as such, 
probably possess specific receptors; and (c) liver and 
submaxillary glands cell populations under study most 
probably lack receptors to factors contained in the as­
sessed tumor extract.
Our findings are in marked contrast to the mitotic 
activity enhancement reported for adult mice (Malm- 
gren 1956; Malmgren & Mills 1961). A similar stimula­
tion was found by our group for 28-day old mice after 
the administration of an extract from EA34, a different 
neoplasia. This is a differentiated mammary carcinoma 
spontaneously originated in the C3H/S strain (Moreno 
et al. 1992). No such proliferation increase was observed 
in intact or regenerating liver when a similar protocol 
was employed in adult mice (Flamini et al. 1996); these 
findings suggest that the extract’s effect on mitosis may 
be age-dependent.
On the other hand, extract preparations from dif­
ferent tumor lines have likewise been found to act neg­
atively on the cell-cycle progression in several cell pop­
ulations. For example extracts from ES2 (Badran et al. 
1985b; Echave Llanos et al. 1986; Errecalde & Echave 
Llanos 1993, fnda et al. 1997) and SS1K hepatocellu­
lar carcinomas (Badran et al. 1985a; Ottino & Echave 
Llanos 1990) have been particularly effective in the in­
hibition of cell-cycle progression. These results clearly 
show that the effects on cell-cycle vary significantly ac­
cording to the type of tumor employed to prepare the 
extract.
The EA21 tumor grafted in the same mice strain 
has a mitogenic effect on enterocytes (Barbeito et al. 
2002a) as well as on renocytes (Catalano et al. 1996). 
These findings suggest that the chronic effect caused by 
a grafted tumor may result opposed to the acute action 
exerted by the same neoplasia extract injection. How­
ever, the stimulating effect promoted by EA21 tumor 
graft has not been found in other cell populations, such 
as pars intermedia cells (Surur et al. 2005).
In coincidence with the present investigation, dif­
ferences among findings in tumor-bearing animals and 
in tumor extract-injected mice have also been demon­
strated for the SS1K hepatocellular carcinoma (Bar­
beito et al. 1997). In this regard, the wide spectrum of 
cell types exhibiting either growth stimulatory or in­
hibitory responses to these different malignant lines ex­
tracts are valuable data that emphasize the need for a 
precise characterization on the nature and specificity of 
the tumor-associated biological activity and host-tissue 
sensitivity relationships.
Considering the growth-retarding agents described, 
the transforming growth factor [3 (TGF/3) family consti­
tutes the most relevant group of substances that have 
been shown to affect kidney convoluted tubules cells 
and intestinal crypts epithelium (Massague 1990; Jiang 
et al. 2003). Nevertheless, these peptides inhibit hepa- 
tocytic proliferation as well (Masuhara et al. 1996; Bre- 
itkopf et al. 2006), a response which we did not observe 
in the present assays. Growth factors that usually pro­
mote cell proliferation may also act as inhibitors under 
certain experimental conditions as revealed by Geimer 
& Bade (1991). In the experiments reported here, ab­
sence of adverse histological or cytological changes in 
tumor extract-treated animals would suggest that the 
action exerted did not occur as a result of non-specific 
toxicity. For this reason, the active components de­
tected in the EA21b tumor extracts may well not cor­
respond to any of the growth factors previously men­
tioned. Yet it is possible that the hepatic response 
was either severely mitigated or altogether prevented 
by some condition, such as animal age (Opleta et al. 
1987) rendering not comparable observations between 
our data and those reported by the above-mentioned 
authors.
Until few years ago, the majority of the substances 
regulating the cell-cycle as external signals were ac­
knowledged to act on the Gx-S phase transition, espe­
cially on cyclin D and cyclin-dependent kinases (CDKs) 
- cyclins complexes. More recently, regulatory sub­
stances affecting gene expression and their products’ 
activity on other cell-cycle phases have been found. 
Some of them include short peptides, e.g. the synthetic 
hexapeptide termed NB11, reported by Canela et al. 
(2006). NB11 binds to a surface pocket in cyclin A and 
inhibits the catalytic activity of the complex cyclin- 
dependent kinase 2-cyclin A required for the cell to 
progress through S phase. However, no natural peptides 
exhibiting a comparable functional role have been iso­
lated from normal or neoplastic tissues. Some growth 
factors well known for their activity, such as tumor 
necrosis factor a (TNFct), can inhibit cyclin A in cer­
tain experimental conditions (Wen et al. 2004). Strik­
ingly, TNFct was previously reported as a stimulating 
agent for the hepatocytic proliferation in regenerating 
liver (Fausto 2000). These facts lead to a clear demon­
stration that the response displayed on cell-cycle to dif­
ferent substances may vary in relation to the cell popu­
lation and the experimental design. In this way, it can 
be hypothesized the possible presence in the EA21 tu­
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mor extract of an antimitotic agent, different than the 
TGF/? family. The resolution of this issue must wait for 
a further characterization of the nature of the mitotic 
activity regulating factor/s in the EA21b tumor.
Acknowledgements
This work was supported with grants from the National Uni­
versity of La Plata. Thanks are due to Mr. Ruben Mario and 
Ms. Paula Dumont for their technical assistance. Animals 
were provided by the Embryology, Biology and Histology 
Institute, School of Medical Sciences, National University 
of La Plata.
References
Badran A.F., Moreno F.R. & Echave Llanos J.M. 1985a. Effect 
of tumour extracts on liver growth: hepatocarcinomas SS1H 
and SS1K. Com. Biol. 2: 143-149.
Badran A.F., Moreno F.R. & Echave Llanos J.M. 1985b. Devel­
opment of the effect of an indifferentiated tumour extract on 
sinusoidal litoral cells of young growing liver. Microsc. Elec­
tron. Biol. Celular 9: 13-21.
Barbeito C.G., Albarenque S.M., Reyna J.C., Flamini M.A., An­
drés Laube P.F. & Badran A.F. 2002a. Mitotic activity of the 
duodenal crypt enterocytes in mice transplanted with EA21a 
mammary carcinoma. Cell Biol. Int. 26: 123-125.
Barbeito C.G., Flamini M.A., García M.N., Andrés Laube P.F., 
Andrini L.B. & Badran A.F. 2002b. Development of compen­
satory hepatic hyperplasia in mice carrying the hepatocellular 
carcinoma ES12a. J. Clin. Exp. Cancer Res. 21: 397-400.
Barbeito C.G., Garcia M.N., Savignone C.A., Catalano V.A., 
Badran A.F., Flamini M.A & Moreno F.R. 1997. Actividad 
mitótica de los epitelios de epidermis, lengua, túbulos con­
torneados renales y conductos de la glándula submaxilar del 
ratón portador del tumor SS1K. Ciencias Morfológicas 3: 9- 
18.
Bjarnason G.A. & Jordan R. 2002. Rhythms in human gastroin­
testinal mucosa and skin. Chronobiol. Int. 19: 129-140.
Breitkopf K., Godoy P., Ciuclan L., Singer M.V. & Dooley, S. 
2006. TGF-R/Smad signaling in the injured liver. Z. Gas­
troenterol. 44: 57-66.
Canela N., Orases M., Fucho R., Mateo F., Gutierrez R., Pineda- 
Lucena A., Bachs O. & Perez-Paya E. 2006. Identification of 
an hexapeptide that binds to a surface pocket in cyclin A and 
inhibits the catalytic activity of the complex cyclin-dependent 
kinase 2-cyclin A. J. Biol. Chem. 281: 35942-35953.
Catalano V.A., Barbeito C.G., Moreno F.R. & Badran A.F. 1996. 
Análisis de la actividad mitótica de la corteza renal en ratones 
portadores del tumor EA21a. Ciencias Morfológicas 2: 3-14.
Echave Llanos J.M., Badrán A.F. & Moreno F.R. 1986. Inhibiting 
effect of a hepatoma extract on the mitotic rate of regenating 
liver. Virchows Arch. (Cell Pathol.) 51: 17-27.
Errecalde A.L. & Echave Llanos J.M. 1993. Effect of ES2 tumor 
extract and plasma of tumor bearing animals on the mitotic 
activity of enterocytes of young mice. J. Exp. Clin. Cancer 
Res. 12: 75-79.
Fausto N. 2000. Liver regeneration. J Hepatol. 32 (Suppl 1): 
19-31.
Flamini M.A., González N.V., Barbeito C.G., Badrán A.F. & 
Moreno F.R. 1996. Study on a tumoral factors stimulant of 
hepatocyte mitosis. Analecta Veterinaria 16: 14-16.
Geimer P. & Bade E.G. 1991. The epidermal growth factor- 
induced migration of rat liver epithelial cells is associated 
with a transient inhibition of DNA synthesis. J. Cell. Sci. 
100: 349-355.
Huitfeldt H., Skarpen E., Lindeman B., Becher R., Thrane V. 
& Schwarze P.J. 1996. Differential distribution of met and 
epidermal growth factor receptor in normal and carcinogen- 
treated rat liver. Histochem. Cytochem. 44: 227-233.
Inda A.M., García A.L., Errecalde A.L. & Badrán A.F. 1997. 
Effect of tissue and plasma factors on kidney proliferation. 
Biocell 2: 13-18.
Jiang B., Zhang J.S., Du J., Urrutia R. & Barnard J. 2003. 
Growth inhibitory signalling by TGF/3 is I)locked in Ras- 
transformed intestinal epithelial cells at a post-receptor locus. 
Cell. Signal. 15: 699-708.
Malmgren R.A. 1956. Observations on a liver stimulant present 
in tumour tissues. Cancer Res. 16: 232-236.
Malmgren R.A. & Mills W. 1961. Studies of properties of the 
liver mitotic stimulant (LMS) in mouse tumor tissue. J. Nat. 
Cancer Inst. 26: 525-532.
Massague J. 1990. The transforming growth factor [3 family 
Annu. Rev. Cell. Biol. 6: 597-641.
Masuhara M., Yasunaga M., Tanigawa K., Tamuta F., Yamashita 
S., Sakaida I. & Okita K. 1996. Expression of hepatocyte 
growth factor, transforming growth factor a and transform­
ing growth factor R1 messenger RNA in various human liver 
diseases and correlation with hepatocyte proliferation. Hepa­
tology 24: 323-329.
Moreno F.R., Badrán A.F. & Flamini M.A. 1992. Effect of tumor 
extracts on the liver proliferation in young mice. Com. Biol. 
10: 336.
Opleta K., O’Loughlin E.V., Shaffer E.A., Hayden J., Hollemberg 
M. & Gall D.G. 1987. Effect of epidermal growth factor on 
growth and postnatal development of the rabbit liver. Am. J. 
Physiol. 253: 622-625.
Ottino A. & Echave Llanos J.M. 1990. Efecto inhibidor del ex­
tracto del hepatocarcinoma transplantado SS1K y del plasma 
de los portadores sobre la actividad mitótica de los hepa- 
tocitos y células litorales del hígado de ratón. Patología 28: 
155-160.
Surur J.M., Catalano V.A., Flamini M.A. & Barbeito C.G. 2005. 
Effects of presence of tumors on the daily mitotic activity of 
mouse pars intermedia. Cell Biol. Int. 29: 173—175.
Wen H.S., Yin Y., Broussard S.R., McCusker R.H., Freund G.G., 
Dantzeri, R. & Kelley K.W. 2004. Tumor necrosis factor o 
inhibits cyclin A expression and retinoblastoma hyperphos­
phorylation triggered by insulin-like growth factor-I induction 
of new E2F-1 synthesis. J. Biol. Chem. 279: 7435-7446.
Received August 23, 2006 
Accepted January 31, 2007
Unauthenticated
Download Date | 8/23/19 11:20 PM
